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Crosstalk between T cells and renal tubular epithelial cells
(TECs) in the pathogenesis of tubular lesions, the most
important sign of progressive renal diseases, has not
been clarified. Previous work has shown that TECs harbor
co-stimulatory signals that promote T-cell activation, which
induces tubular lesions. Nevertheless, the expression and
functional role of B7-H4, a recently identified co-stimulatory
ligand of the B7 superfamily, in pathologic human kidneys is
unclear. We investigated the expression of B7-H4 on cryostat
renal biopsies from patients with idiopathic membranous
nephropathy (n¼ 20), immunoglobulin A nephropathy
(n¼ 19), lupus nephritis (n¼ 16), and acute renal allograft
rejection (n¼ 15) using immunohistochemistry. In addition,
we also analyzed TEC-associated B7-H4 in the regulation of
T-cell activation. Immunohistological staining revealed that
B7-H4 antigen is restricted to tubular epithelium and that the
protein is prominent in sections with severe tubular lesions,
although no correlation was observed between tubular
B7-H4 expression and levels of serum creatinine, serum urea
nitrogen concentration, and 24-h proteinuria in each type of
nephropathy. In vitro, mixed lymphocyte reactions revealed
that TEC-related B7-H4 promotes cytokine (interleukin-2
and interferon-c) production and proliferation of co-cultured
T cells. Interestingly, the secretion of interleukin-2 by
C10 T cell hybridomas also increased when C10 cells were
co-cultured with the B7-H4-transgenic murine TEC line,
3M-1-secreting tubular epithelial cells (MCT) in the presence
of the antigen hen egg lysozyme. Our results clearly
show that TEC-associated B7-H4 induces T-cell activation
and we propose that B7-H4 is a potential activator that
promotes tubular lesion.
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Tubular injury is the most reliable predictor of clinical
outcome in chronic glomerular diseases.1–3 Activated tubulo-
interstitial infiltrating T cells supply the local environment
with proinflammatory factors such as tumor necrosis
factor-a (TNF-a) and interferon-g (IFN-g), which have been
demonstrated to actively participate in tubular pathogen-
esis.2,4 It is now accepted that the optimal activation of T cells
requires both co-stimulation and T-cell receptor engagement,
and antigen presentation in the absence of co-stimulation
may lead to T-cell anergy, tolerance, or apoptosis.5
Renal tubular epithelial cells (TECs) become capable
of effective antigen presentation and attract T cells into
the tubulointerstitium, which has been confirmed by the
contemporary aberrant expression of major histocompat-
ibility complex II antigens (MHC-II) and intercellular
adhesion molecule-1 (ICAM-1). Additionally, TECs are also
induced to express several kinds of co-stimulatory molecules
under inflammatory conditions, which supply secondary
signals for T-cell activation. It has been confirmed that
co-stimulatory molecules such as B7.1, B7.2, inducible
co-stimulator ligand (ICOSL), or CD40 expressed by TECs
actively take part in the pathogenesis of tubular lesions.6–9
Selective manipulation of CD28/B7.1, B7.2, CD154/CD40,
or inducible co-stimulator ligand/inducible co-stimulator
(ICOSL/ICOS) pathways have also been demonstrated to
be beneficial in the therapy for autoimmune nephritis
and renal allograft rejection.7 Recently, several members of
the B7 superfamily have been identified, including B7-H1,10
B7-DC,11 B7-H3,12 and B7-H4.13 Elucidating the functional
characteristics of these co-stimulatory ligands in renal
diseases is currently the subject of intense research.
B7-H4, also known as B7x14 or B7S1,15 is a recently
identified member of the B7 family that is known to be
critically involved in the downregulation of antigen-specific
immune responses.13 B7-H4 exerts its physiologic function
by binding to a receptor on T cells which in turn induces
cell cycle arrest and inhibits the secretion of cytokines and
the development of cytotoxicity.13–15 B7-H4 mRNA, but not
protein expression, has been detected in a wide range of
normal somatic tissues, including liver, skeletal muscle,
pancreas, and the small bowel. Surface expression of B7-H4
protein, on the other hand, is restricted to activated T cells, B
cells, monocytes, and dendritic cells (DCs). Recently, aberrant
B7-H4 protein expression has also been reported in several
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human malignancies.16–21 Nevertheless, the significance of
B7-H4 expression in human kidneys has not been described.
Herein, we investigate B7-H4 expression on cryostat sections
from patients with various nephropathies and define its clinical
significance. Moreover, we also performed mixed lymphocyte
reactions (MLRs) to detect the potential role of TEC-associated
B7-H4 in the regulation of T-cell activation in vitro.
RESULTS
Detection of B7-H4 antigen in renal biopsies
Double labeling with B7-H4-PE (phycoerythrin) and CK-18-
FITC (fluorescein isothiocyanate) monoclonal antibodies
(mAbs) indicated that B7-H4 antigen was restricted to tubule
epithelium and the expression was absent on cells within the
tubulointerstitial space or glomeruli of diseased kidneys
(Figure 1). Immunohistochemical assays indicated that
B7-H4 expression in sections with severe tubular lesions
(tubular lesions of Grades 2 and 3) was much stronger than
in sections with minor tubular lesions (Grade 1). Moreover,
only two cases of immunoglobulin A (IgA) nephropathy and
two cases of idiopathic membranous nephropathy (IMN)
without detectable tubular lesions (Grade 0) were faintly
positive for B7-H4 antigen. Interestingly, we did not find
B7-H4 expression by normal kidneys (Figure 2).
The percentage of B7-H4þ tubules in IMN was 16.267
20.82% (mean7s.d.; median, 13.7%), whereas in IgA
nephropathy it was 14.67721.12% (mean7s.d.; median,
11.3%). The percentage of B7-H4þ tubules in acute renal
allograft rejection was slightly larger (mean7s.d., 37.67
23.2%; median, 15.6%) than that in lupus nephritis (mean7s.d.,
a
d
b
e
c
f
20 m
20 m
20 m
20 m
20 m
20 m
Figure 1 | Expression of B7-H4 was restricted in renal tubular epithelium. Human renal tissues were stained with (d) CK-18-FITC and
(e) B7-H4-PE mAbs and analyzed by laser scanning confocal microscopy. Results indicated that B7-H4 antigen was only detected in tubule
epithelium (T). Nevertheless, no B7-H4 expression was found on cells within tubulointerstitial space or glomeruli (g). Here, sections incubated
with (a) mouse IgG1-FITC and (b) IgG1-PE mAbs were used as isotype control. (c) Represents the merge of (a) and (b) images and
(f) indicates the merge of (d) and (e) images. Here, representative sections from patients with IgA nephropathy were shown. Bar¼ 20 mm.
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Figure 2 | Immunohistochemical assay of B7-H4 antigen on diseased and normal cryostat renal tissues. Data evidenced that strong
B7-H4 protein was detected in the tubular epithelium of sections with severe tubular lesions (Grade 3) of patients with (a) IMN, (b) acute
renal allograft rejection, (c) IgA nephropathy, and (d) a representative patient with lupus nephritis with Grade 2 tubular lesions. (e) Slight
B7-H4 expression on tubular epithelium was detected in sections from IgA nephropathy without tubular lesions (Grade 0). (f) B7-H4
protein expression was absent in normal renal tissues. Original magnification  200.
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26.5735.2%; median, 9.7%; Figure 3a). The mean percen-
tage of B7-H4þ tubules in all calculated sections was 11.6%.
Statistical analysis revealed B7-H4 expression was not signifi-
cantly different among these five types of nephropathies (data
not shown).
Clinical significance of B7-H4 expression
We further compared B7-H4 expression with clinico-
pathological variables. Patients were divided into two groups
using the median percentage number of B7-H4þ tubules as
the distinguishing factor. Results showed that no correlation
was observed between tubular B7-H4 expression and levels of
serum creatinine, blood urea nitrogen, albumin, or 24-h pro-
teinuria for each type of nephropathy (Table 1). In addition,
no correlation was found between B7-H4 expression and
patients’ age or gender (data not shown).
We also examine a possible relationship between B7-H4
expression and the severity of tubular lesions. Here, patients
were divided into four groups using the scores of tubular
lesions as a cutoff. As shown in Figure 3b, although
occasional expression of B7-H4 was found in sections with
slight tubular lesions, significant B7-H4 protein was detected
in severe cases. Statistical analysis indicates they are
significantly different (Po0.05). These results suggest that
tubular-associated B7-H4 might be a suitable marker for
predicting tubular lesions.
Functional relevance of B7-H4 expression on TECs:
promotion of cytokine production and cell proliferation
of co-cultured T cells
To induce B7-H4 antigen on TECs, human primary TECs
were stimulated with proinflammatory factors including
TNF-a (10 ng/ml), IFN-g (200 U/ml), lipopolysaccharide
(LPS) (10 ng/ml), and interleukin (IL)-10 (10 pg/ml) in
combination for the indicated duration. The total RNA
from 3 105 collected TECs was isolated and B7-H4 mRNA
transcription was measured by semiquantitative reverse
transcriptase polymerase chain reaction analysis (RT-PCR).
As shown in Figure 4a, RT-PCR indicated that the upregu-
lation of B7-H4 mRNA transcription was already detectable
after 24 h of treatment with the inflammatory factor cocktail,
reach a maximum at 72 h, and gradually decline thereafter.
Flow cytometry as well as Western blotting assays also
revealed that B7-H4 protein expression on TECs was driven
by these inflammatory factors (Figure 4b and c).
MLRs were used to test the effect of TEC-related B7-H4
on T-cell activation. Confluent TECs (1 104) were preincu-
bated with the inflammatory factor cocktail to induce B7-H4
antigen. After 72 h, purified CD3þ T cells (1 105) were added
to the culture in the presence of anti-CD3 mAb (2mg/ml), B7-
H4-blocking mAb (hH4.1, 20 mg/ml), or isotype control mAb
(mouse IgG1, 20 mg/ml). Supernatants were collected to assay
the secretion of cytokines by enzyme-linked immunosorbent
assay (ELISA) after 72 h. As shown in Figure 5a, the
production of IFN-g and IL-2 was increased when T cells
were co-cultured with TECs compared to T cells cultured
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Figure 3 | Calculation of B7-H4þ tubuli on diseased kidneys.
(a) Median B7-H4 staining intensity values in diseased renal tissues.
The horizontal bar indicates median staining intensity within each
diagnostic category. 1: IMN (n¼ 20); 2: IgA nephropathy (n¼ 19);
3: lupus nephritis (n¼ 16); and 4: acute renal allograft rejection
(n¼ 15). (b) Expression of B7-H4 in sections with different scores
of tubular lesions. The severity of tubular lesion was graded based on
results of H & E staining. Tubular B7-H4-positive staining intensity was
scored into four grades. Grade 0: no positive tubular staining; Grade
1: p20% positive tubules; Grade 2: 20–50% positive tubules, and
Grade 3: X50% positive proximal tubules.
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Figure 4 | Detection of B7-H4 mRNA transcription and protein
expression on primary human TECs. (a) Semiquantitative RT-PCR
revealed the time-dependent upregulation of B7-H4 mRNA tran-
scription by primary human TECs stimulated with TNF-a (10 ng/ml),
IFN-g (200 U/ml), IL-10 (10 pg/ml), and LPS (1 mg/ml). Here, total RNA
from 3 105 TECs was analyzed. b-Actin cDNA was used as an
internal control for mRNA transcription. (b) Flow cytometry and (c)
Western blot analyses also revealed the upregulation of B7-H4
protein expression by treatment with proinflammatory factors. Here,
b-actin protein was used as an internal control for protein loading.
One of three representative experiments was shown.
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alone in the presence of anti-CD3 (2mg/ml). Interestingly, the
secretion of both cytokines was decreased when TEC-
associated B7-H4 signals were blocked using anti-B7-H4
mAbs (the level of IL-2 decreased from 215.3 to 107.7 pg/ml
(Po0.05), and IFN-g decreased from 121.7 to 65.4 pg/ml
(Po0.05)). Similar results for the TEC-related B7-H4
promotion of T-cell proliferation were also detected in the
MLRs (Figure 5b). These results confirmed that B7-H4
mediates stimulatory signal, which upregulates T-cell prolif-
eration and cytokine production in our experimental system.
B7-H4 upregulates antigen presentation by murine TECs
MLRs were also used to assay B7-H4 function in antigen
presentation. Figure 6 indicates that B7-H4 protein is absent
in the murine TEC cell line MCT. Before co-culture
experiments, MCT cells were transfected to stably express
B7-H4 protein, as confirmed by flow cytometry as well as
Western blot analysis.
MCT cells were co-cultured with C10 T cells in the
presence or absence of foreign antigen hen-egg lysozyme
(6 mg/ml). After 48 h, supernatants were collected to detect
Table 1 | Expression of B7-H4 on renal tubules has no statistically significant correlation with clinicopathological characteristics
of patients with different renal diseases
Clinical/histologic diagnosis
Number
of cases B7-H4 statusa
Serum creatinine
(lmol/l)
Urea nitrogen
(mg/l)
24-h proteinuria
(g/day)
IMN 11 XMedian 107.20722.45 25.3277.69 2.2971.35
9 oMedian 131.27717.12 20.1376.73 3.8272.49
IgA nephropathy 8 XMedian 131.21726.11 20.0275.20 2.2171.64
11 oMedian 122.33728.79 23.1775.66 1.4370.96
Lupus nephritis 7 XMedian 112.19720.03 13.9173.06 2.8571.39
9 oMedian 109.15727.27 12.7973.11 2.3771.66
Acute allograft rejection 8 XMedian 96.08720.22 17.6777.54 2.0171.68
7 oMedian 89.31717.57 22.0877.09 1.6971.87
IgA, immunoglobulin A; IMN, idiopathic membranous nephropathy.
aThe median percentage of B7-H4 positive tubules in IMN was 13.7%, in IgA nephropathy 11.3%, in lupus nephritis 9.7%, and in acute renal allograft rejection 15.6%.
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Figure 5 | B7-H4 promotes epithelial-dependent T-cell cytokine
production and proliferation. (a) B7-H4 promotes epithelial-
dependent T-cell cytokine production. Purified human CD3þ T cells
(1 105) were co-cultured with proinflammatory factors-activated
primary human TECs (1 104) in the presence of anti-CD3 (2 mg/ml),
B7-H4-blocking mAb (hH4.1, 20 mg/ml), or mouse IgG1 isotype
control mAbs (20 mg/ml). Supernatants were collected to assay IL-2
and IFN-g secretion by ELISA after 72 h. The data show that the
secretion of both cytokines decreased when TEC-associated B7-H4
signals were blocked with a B7-H4-blocking mAb. (b) TEC-associated
B7-H4 promoted cell proliferation of co-cultured T cells. Cell
proliferation was significantly decreased when B7-H4-blocking mAbs
(hH4.1, 20 mg/ml) were added to this co-culture system. *Po0.05 and
**Po0.01 when compared with isotype control. One of three
representative experiments was shown.
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Figure 6 | B7-H4 promotes antigen presentation. (a) Flow
cytometry revealed that B7-H4 protein is absent in the murine TEC
line MCT. Nevertheless, stable expression of this protein by MCT cells
was found after transfection with the murine B7-H4 gene. (b) Western
blotting assay revealed stably expressed B7-H4 protein by MCT cells
after the B7-H4 gene was transfected. (c) B7-H4 promoted IL-2
production by co-cultured C10 T cell hybridoma cells (hen-egg
lysozyme antigen specific, I-Ak restricted) after antigen (hen-egg
lysozyme antigen, 6 mg/ml) presentation by B7-H4 gene-transfected
MCT cells. The release of IL-2 by C10 T cells (48 h) was detected
by ELISA. Here, cells cultured in the presence of Rat IgG1 mAbs
were used as an isotype control. Data are pooled from at least
three independent experiments with similar results. *Po0.05
and **Po0.01 when compared with isotype control.
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IL-2 production. As shown in Figure 6c, transfection of
B7-H4 significantly promoted the production of IL-2 by C10
T hybridoma cells. Additionally, blocking B7-H4 signals with
a specific, blocking mAb (clone 188, 20 mg/ml) reversed the
stimulatory effect of B7-H4 and resulted in decreased
antigen-specific IL-2 production by C10 cells. In addition,
the activation of C10 cells required antigen presentation by
major histocompatibility complex molecules, as evidenced
by the inhibition of IL-2 secretion by blocking I-Ak with a
major histocompatibility complex II-specific mAb (clone 10-
3.6). These results further indicated that TEC-associated B7-
H4 is a stimulator of T-cell responses.
DISCUSSION
It is well established that members of the B7 family of
co-stimulatory ligands provide positive and negative signals
and play a central role in the regulation of antigen-specific,
T-cell-mediated immune responses.22,23 B7-H4 is a recently
discovered co-stimulatory molecule of the B7 family that
regulates T-cell activation.13,15 Based on flow cytometric
analysis, expression of B7-H4 protein was reported to be
inducible upon stimulation of T cells, B cells, monocytes, and
DCs, whereas immunohistochemistry revealed little expres-
sion in several peripheral tissues with the exception of
positive staining on some carcinomas.18,19,24 In this study,
an abundance of renal biopsies were tested for B7-H4 protein
expression and the results show that although B7-H4 antigen
is absent in normal kidneys, significant B7-H4 antigen is
detected in diseased cases included IMN, IgA nephropathy,
lupus nephritis, and acute renal allograft rejection.
Double labeling indicated that B7-H4 antigen is only detected
on tubule epithelium but not on cells within the tubulointer-
stitial space or glomeruli. Moreover, vascular endothelial cells
did not express B7-H4 in these tissues (data not shown).
These results are inconsistent with the results from renal cell
carcinoma reported by Krambeck et al.,20 who found B7-H4
expression on tumor cells and the tumor vasculature of renal
cell carcinoma. In vitro, B7-H4 protein is profoundly induced
in primary human TECs upon stimulation with IL-10, LPS,
TNF-a, and IFN-g in combination. Our results are the first to
demonstrate that B7-H4 is a co-stimulatory ligand that can
be induced in TECs in vivo and in vitro.
Sections with severe tubular lesion observed in many renal
autoimmune diseases and acute renal transplant rejection are
associated with T cells infiltrating into tubulointerstitium,
and these infiltrating T cells could secrete inflammatory
cytokines to promote tubular atrophy and interstitial
fibrosis.25 On the other hand, it is well known that co-
stimulatory molecules CD80, CD86, and CD40 on TECs also
play a central role in the pathogenesis of such tubular lesions,
they favor direct interactions between tubular cells and
interstitial T cells.23 We here show that B7-H4 is majored in
sections with severe tubular lesion, a similar pattern of T-cell
infiltration in diseased kidneys reported previously.25 In vitro,
B7-H4 mRNA transcription and protein expression is also
induced by proinflammatory factors. These results indicate
that B7-H4 expression is possibly induced by factors secreted
by infiltrating T cells within tubulointerstitium.
B7-H4 binds to a putative receptor expressed on activated
but not naive T cells and thereby leads to inhibition of T-cell
activation and IL-2 production.13–15 B7-H4 does not interact
with receptors for other B7 family members including CD28,
ICOS, cytotoxic T-lymphocyte antigen 4 (CTLA-4), or
program death-1 (PD-1) and, to date, the specific identity
of the cell-surface receptor that binds B7-H4 has not been
identified. A receptor named B and T lymphocyte attenuator
(BLTA) has been proposed for B7-H4 based on indirect
evidence.14,26 However, B7-H4 and BTLA do not interact
with each other in direct binding experiments, and
herpesvirus entry mediator is regarded as the ligand for
BLTA.27 Despite the lack of a defined B7-H4 receptor, our
results described here provide clear evidence that B7-H4
binding to a receptor expressed on co-cultured T cells or C10
T hybridoma cells. MLRs indicated that TEC-related B7-H4
is a stimulator that promotes co-cultured T-cell activation, as
confirmed by the secretion of IFN-g and IL-2 as well as the
proliferation was decreased when B7-H4 is blocked using
antibodies. In addition, transfected expression of B7-H4 by
the murine TEC cell line MCT also promoted antigen
presentation. Our results are inconsistent with the concept of
an overall negative regulatory function for B7-H4 in T-cell
activation13,14 and we propose that B7-H4 might play a
stimulatory role in TEC-mediated immune activation and
immunopathology within kidneys.
The existence of two different receptors with opposing
signaling outcomes has been documented for all B7 super
family members until now. B7.1 and B7.2 bind to CTLA-4 on
activated T cells to mediate a negative signal and to CD28 on
resting cells to provide a co-stimulatory signal.23 Over-
whelming evidence suggests that B7-H1 (PD-L1) and B7-DC
(PD-L2), two members of the B7 family which are normally
expressed by macrophage lineage cells and are also abundant
in a variety of cancers,28 are negative regulators of T-cell
responses through engagement with PD-1.29–32 Nevertheless,
several studies indicate that B7-H1 and B7-DC can stimulate
T-cell activation through engagement with as yet unidentified
receptors.33 Moreover, TEC-associated B7RP-1 provides an
inhibitory signal to downregulate T-cell activation,6 although
robust evidence indicates that B7RP-1 is a co-stimulator.34,35
Interestingly, double functions for B7-H3 in T-cell activation
have also been reported.33 Our data suggest that B7-H4 can
promote T-cell cytokine production and proliferation and
reveal a new proinflammatory function for this protein aside
from its ability to inhibit immune cell function as mentioned
previously. Experiments from our laboratory are underway to
define the players and signaling pathways that are associated
with B7-H4.
TECs are known as active cells that play an important role
in the pathogenesis and progression of renal diseases. They
can produce a wide variety of inflammatory mediators,
including cytokines (IL-1a, IFN-g), chemokines (monocyte
chemoattractant protein-1, -4, and osteopontin), and com-
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plement proteins (C3, C5).36 Recent studies suggest that
TECs might also function as antigen-presenting cells involved
in the pathogenesis of nephritis, and that co-stimulatory
molecules including ICAM-1, vascular cellular adhesion
molecule-1 (VCAM-1), CD40, and several members of the
B7 superfamily, such as B7.1, B7.2, and B7RP-1, have been
reportedly expressed by TECs and are involved in pathogen-
esis.37 Recently, we also found that B7-H138 was expressed by
TECs. These co-stimulatory molecules could provide positive
(B7.1, B7.2, and CD40) or negative (B7-H1 and B7RP-1)
signals to T cells that determine an optimal T-cell response.
Our results indicate that TEC-related B7-H4 is a co-stimu-
lator and we suggest that this antigen may be involved in the
pathogenesis of nephritis.
An increasing amount of data suggests that tubular lesions
are predictive of progression in glomerulopathies.25,39 Data
from follow-up (10 years) analyses revealed that renal
survival rate was significantly higher in patients with low-
grade tubular lesions than those with high-grade tubular
lesions in IgA nephropathy as well as lupus nephritis.40 We
demonstrate that B7-H4 expression is restricted to sections
with severe tubular lesion; however, the effect of B7-H4 on
renal survival is not presented here. Additional studies are
needed to test the role of B7-H4 in renal survival.
In summary, we show that B7-H4 is overexpressed in a
majority of renal tissues with serious tubular lesions, whereas
little or no expression is found in normal cases. In vitro, we
show conclusively that B7-H4 protein in TECs is induced by
proinflammatory factors and that it promotes T-cell activa-
tion. These data provide a new function for overexpressed
B7-H4 on TECs. Our new data validate B7-H4 as a promising
new target for immunotherapy of renal diseases.
MATERIALS AND METHODS
Antibodies and reagents
Mouse anti-human B7-H4 mAb (clone hH4.1) was kindly provided
by Professor Lieping Chen (School of Medicine, Johns Hopkins
University, Baltimore, USA), which has been used previously for
blocking experiments and detecting B7-H4 antigen on some cancer
tissues.17,20,41 PE anti-human B7-H4 (clone H74), rat anti-mouse
B7-H4 (clone 188) mAb, anti-human CD3 (clone UCHT1) mAb,
and goat anti-mouse or anti-rat secondary antibodies (IgG1) were
bought from eBioscience (San Diego, CA, USA). Rat anti-murine I-
Ak (clone 10-3.6) mAb was bought from BD PharMingen (San
Diego, CA, USA). LPS, recombinant human TNF-a, IL-10, and IFN-
g were purchased from PeproTech (London, UK). Human IFN-g, IL-
2, and mouse IL-2 ELISA kits were obtained from Diaclone Research
(Besanc¸on, Cedex, France).
Renal biopsies and tubular grading
One hundred and thirteen renal core needle biopsies from
patients with IMN, IgA nephropathy, lupus nephritis, or acute
renal allograft rejection were collected at the Department of
Nephrology, Xinqiao Hospital and the Department of Pathology,
South-West Hospital (Chongqing, PR China) from January 2002 to
December 2005 with the approval of the local Institutional and
Ethics Review Boards. Seventy patients whose clinical parameter
records were intact and whose fresh-frozen tissues were available
were selected. These are including: (1) IMN (n¼ 20); (2) IgA nephro-
pathy (n¼ 19); (3) lupus nephritis (type II (n¼ 4), type III (n¼ 6),
and type IV (n¼ 9)); and (4) acute renal allograft rejection (n¼ 15).
In addition, three pretransplant biopsies of healthy organ donors are
also selected.
Clinical parameters at the time of renal biopsy analyzed in this
study included age, gender, serum creatinine, serum urea nitrogen
concentration, and 24-h proteinuria at the time of diagnosis. Other
clinicopathological variables were made independently by histologic
and immunohistologic examination of each biopsy.
Analysis of tubular lesions was based on hematoxylin and eosin
staining and the grade of severity was divided into four major
categories that have been described by Daniel et al.,42 as follows:
Grade 0: all tubules are normal and show a regular basal membrane;
Grade 1: a focus of tubules have a thickened wrinkled basal
membrane, and tubular lesions involve less than 25% of the cortical
area; Grade 2: a few tubules are normal within an area with
inflammation and fibrosis, and tubular lesions involve less than 50%
but more than 25% of the cortical area; and Grade 3: all tubules have
irregular and thickened basal membrane, and diffuse tubular lesions
involve more than 50% of the cortical area (Figure 7).
Immunohistochemical assay
An immunohistochemical assay was used to detect B7-H4 antigen
expression. Briefly, renal tissues were cut (6–8 mm) and fixed in
acetone for 10 min. Endogenous peroxidase activity was blocked
with 0.03% hydrogen peroxide in methanol for 30 min and sections
were incubated with primary mouse anti-human B7-H4 (hH4.1)
mAb overnight at 41C. Sections were then incubated with the
secondary antibody EnVisionþ TM (EnVisionTM System, horseradish
peroxidase, mouse/rabbit, Dako, Denmark) for 30 min. Slides were
rinsed in phosphate-buffered saline after each step. Negative
controls were obtained by omitting the primary antibodies or using
irrelevant Ig. Reactivity was detected with a DAB Elite kit (K3465,
Dako) and positive staining was detected as a brown coloration
of the tissues.
a b
dc
Figure 7 | Tubular lesion grading is scored according to results of
hematoxylin and eosin (H&E) staining. (a) All tubules were normal
and showed a regular basal membrane, Grade 0; (b) a focus of tubules
had a thickened and wrinkled basal membrane, Grade 1; (c) a few
tubules were normal within an area with inflammation and fibrosis,
Grade 2; (d) all tubules had irregular and thickened basal membrane,
Grade 3. All sections shown here were obtained from lupus nephritis
patients. G, glomerule; T, tubule. Original magnification  200.
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Expression of B7-H4 was also defined by immunohistochemistry
using B7-H4-PE and cytokeratin-18-FITC mAbs (CK-18, a well-
characterized marker of epithelial cells) double labeling. Sections
incubated with mouse IgG1-PE and IgG1-FITC mAbs were used as
isotype controls. Results were analyzed by laser scanning confocal
microscopy (Leica TCS NT, Leica, Germany).
Quantitative assay of B7-H4þ tubuli
B7-H4þ tubuli were counted with using an eyepiece graticule to
identify 10 microscopic fields (original magnification  200). The
number of tubules with clearly identifiable B7-H4 expression and total
tubules was counted, and the intensity was expressed as the percentage
of tubules bearing B7-H4 antigen. In addition, tubular B7-H4-positive
staining intensity was scored into four grades. Grade 0: no positive
tubular staining; Grade 1: p20% positive tubules; Grade 2: 20–50%
positive tubules, and Grade 3: X50% positive proximal tubules.
Detection of B7-H4 mRNA transcription
The production of primary human TECs has been described in our
previous work.38 To induce B7-H4 expression, human primary
TECs cultured in 12-well plates (1 105 cells/well) and cells were
stimulated with LPS (10 ng/ml), IL-10 (10 ng/ml), TNF-a (10 ng/
ml), and IFN-g (200 U/ml) in combination for the indicated
duration. RT-PCR was used to analyze the expression of B7-H4
mRNA by cultured TECs. Total RNA from 3 105 collected TECs
was isolated by the tripure isolation reagent kit (Promega, San Luis,
Obispo, USA). All RNA samples were quantitated by measurement
of optical density at 260 nm. Semiquantitative RT-PCR is performed
using a two-step PCR kit in accordance with the manufacturer’s
instructions (Takara, Otsu, Japan). Specific primer sequences for
B7-H4 were sense: 50-GTCGGAGCAGGATGAA-30 and antisense:
50-GAAGCCTTTGAGTTTAGC-30, the product length was 507 bp.
PCR products were separated by electrophoresis on a 1% agarose gel
and visualized by ethidium bromide staining, and results are analyzed
by PhosphorImager (PDQUEST, Bio-Rad, Hercules, CA, USA).
Western blot
B7-H4 expression by inflammatory factor-activated human primary
TECs was tested via Western blot. Briefly, cells (1 106) were
washed twice and lysed with 600ml of T-PER TM reagent (Pierce,
Rockford, IL, USA). After gentle shaking for 5 min, the extracts were
centrifuged at 13 000 r.p.m./min for 8 min at room temperature.
Supernatants were mixed with 2 sodium dodecyl sulfate reducing
sample buffer (0.38 M Tris base, 8% sodium dodecyl sulfate, 8%
b-mercaptoethanol, 4 mM ethylenediaminetetraacetate, 40%
glycerol, 0.05% bromphenol blue, pH 6.8) and heated for 10 min.
Equal amounts of protein extracts (3 mg) were separated with 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins
were then transferred to polyvinylidene difluoride membranes
(0.45mm pore size; Bio-Rad, Hercules, CA, USA). B7-H4 was
detected with a chemiluminescence detection system (Tropix,
Bedford, MA, USA) and emitted light was detected by X-ray film
(Kodak, Beijing, PR China). b-Actin protein was used as a protein
loading control.
Flow cytometry
Surface expression of B7-H4 on primary human TECs or the mouse
TEC lines MCT and C1.1 was quantified by flow cytometry on a
fluorescence-activated cell sorter (FACsAria cytometer, Becton
Dickinson, Heidelberg, Germany). For each analysis, 10 000 cells
were evaluated. Flow cytometric data were analyzed using
CELLQuestTM software (BD Biosciences, San Jose, CA, USA).
Mixed lymphocyte reactions
MLRs were carried out to detect TEC-associated B7-H4 function. For
matched comparisons, venous blood was collected from patients
whose renal tissues were used for primary TEC establishment.
Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque
(1.077 density) and resuspended in Roswell’s Park Memorial Institute
1640 medium. CD3þ T cells (495%) were further separated using
microbeads (Miltenyi Biotech, Bergish, Gladbach, Germany) as
described previously.24 Before co-culture, 2 104 harvested TECs
were seeded into 24-well plates and preincubated with a proin-
flammatory factor cocktail to induce B7-H4 antigen expression. After
72 h, cells were washed and freshly isolated T cells (2 105) were
added in the presence of anti-CD3 mAb (UCHT1, 2mg/ml) together
with anti-B7-H4-blocking mAb (hH4.1, 20mg/ml) or anti-CD3 mAb
plus isotype control antibody (mouse IgG1, 20mg/ml). Here, T cells
cultured alone in the presence of anti-CD3 (UCHT1, 2mg/ml) or T/
TECs co-culture in the presence of anti-CD3 but not the presence of
other mAbs (medium) were used as a negative control. For the
measurement of cytokine (IL-2 and IFN-g) production, supernatants
were removed after 72 h and analyzed by ELISA. For analysis of cell
proliferation, cultures were pulsed with [3H]thymidine during the last
18 h of a total 72 h co-culture, and T cells were harvested with glass
fiber filters and counted with a 1450 MicroBeta scintillation counter
(Perkin-Elmer Wallac, Gaithersburg, MD, USA).
Murine B7-H4 gene transfection and antigen presentation
assay
A complementary DNA fragment encoding the entire open reading
frame of murine B7-H4 was prepared by RT-PCR from BALB/c
mouse peritoneal macrophages. A forward primer (50-CGGGATT-
CATGGCTTCCTTGGGGCA-30) corresponding to nucleotide 1–17
of murine B7-H4 complementary DNA14 tagged with a BamH1 site
and a reversed primer (50-CGGAATCCTCATCTTAGCATCAGGC
AACAG-30) corresponding to nucleotide 831–852 tagged with an
EcoRI site were used as the 50 and 30 primers, respectively. The PCR
product was cloned into the PCI-neo vector and transfected into
cells of the mouse TEC line MCT (kindly provided by Professor RP
Wu¨thrich, Division of Nephrology, Kantonsspital St Gallen, Switzer-
land) with Lipofectin (Invitrogen, Carlsbad, CA, USA). After 2
months of selection with G418 (200 mg/l, Sigma-Aldrich, St Louis,
MO, USA), transfectants with stable expression of B7-H4 protein
were identified by Western blot and flow cytometry.
The C10 T hybridoma was also kindly provided by Professor RP
Wu¨thrich, this cell line has been used to detect TEC-associated B7RP-
1 and B7-H1 function.6,43 Antigen presentation was performed as
described previously.38 Briefly, 1 105 collected B7-H4-transfected
MCT cells were co-cultured with 1 105 C10 T cells in the presence
of hen-egg lysozyme antigen (6 mg/ml). After 48 h, supernatants were
collected to detect IL-2 by ELISA. In some experiments, blocking
mAbs against murine B7-H4 (clone 188, 20mg/ml) or rat-IgG (20mg/
ml) were added to culture and used for control.
Statistical analysis
All values from cytokine production (ELISA) and cell proliferation
([3H]thymidine radioisotope count per minute, CPM) were
expressed as the mean7s.e.m. of three separate experiments.
Statistical significance was based on the results of one-way analysis
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of variance. In addition, w2 test was used in this study to analyze the
relationship between tubular B7-H4þ values and tubular lesion. P-
value o0.05 was considered to be statistically significant.
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